Detalhe da pesquisa
1.
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.
J Eur Acad Dermatol Venereol
; 37(3): 549-557, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376738